Quadrant Capital Group’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-267
Closed -$7.38K 2722
2023
Q4
$7.38K Buy
267
+259
+3,238% +$15.8K ﹤0.01% 2170
2023
Q3
$460 Hold
8
﹤0.01% 2578
2023
Q2
$497 Hold
8
﹤0.01% 2570
2023
Q1
$481 Buy
8
+5
+167% +$571 ﹤0.01% 2610
2022
Q4
$408 Buy
+3
New +$423 ﹤0.01% 2647
2022
Q2
Sell
-6
Closed -$1K 2538
2022
Q1
$1K Buy
6
+3
+100% +$396 ﹤0.01% 2251
2021
Q4
$1K Sell
3
-2
-40% -$472 ﹤0.01% 2255
2021
Q3
$1K Sell
5
-36
-88% -$10.3K ﹤0.01% 2257
2021
Q2
$17K Buy
41
+26
+173% +$10.3K ﹤0.01% 1278
2021
Q1
$6K Buy
15
+4
+36% +$1.97K ﹤0.01% 1703
2020
Q4
$6K Sell
11
-9
-45% -$5.7K ﹤0.01% 1619
2020
Q3
$14K Buy
20
+4
+25% +$3.12K ﹤0.01% 1094
2020
Q2
$13K Sell
16
-37
-70% -$27.9K ﹤0.01% 1218
2020
Q1
$32K Buy
53
+12
+29% +$11.7K 0.01% 1079
2019
Q4
$46K Buy
41
+9
+28% +$9.78K 0.01% 1380
2019
Q3
$38K Buy
32
+4
+14% +$6.11K 0.01% 1332
2019
Q2
$45K Sell
28
-10
-26% -$17.3K 0.01% 1259
2019
Q1
$74K Buy
38
+26
+217% +$45.8K 0.01% 969
2018
Q4
$15K Hold
12
﹤0.01% 1266
2018
Q3
$22K Hold
12
0.01% 932
2018
Q2
$24K Hold
12
0.01% 898
2018
Q1
$26K Hold
12
0.01% 850
2017
Q4
$27K Hold
12
0.01% 817
2017
Q3
$21K Hold
12
0.01% 880
2017
Q2
$16K Hold
12
0.01% 930
2017
Q1
$14K Hold
12
0.01% 953
2016
Q4
$9K Hold
12
﹤0.01% 1050
2016
Q3
$10K Hold
12
0.01% 1042
2016
Q2
$6K Buy
+12
New +$6.8K ﹤0.01% 1158
2015
Q3
Sell
-4
Closed -$8K 1273
2015
Q2
$8K Buy
+4
New +$8.15K 0.01% 743

Other funds holding BLUE

Quadrant Capital Group's BLUE Position: Q1 2024 in Review

Quadrant Capital Group sold out of bluebird bio (BLUE) in Q1 2024, closing a stake of 267 shares — an estimated $7.38K sold.

Quadrant Capital Group first reported a position in BLUE in Q2 2015 and held it in 30 quarters. The position peaked at $74K in Q1 2019. 158 funds tracked by Wall St. Rank hold BLUE as of Q1 2024.

  • Quadrant Capital Group reported no remaining bluebird bio position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 267 bluebird bio shares in Q1 2024, an estimated $7.38K.
  • Quadrant Capital Group first reported a position in bluebird bio in Q2 2015 and held it in 30 quarters.
  • Quadrant Capital Group's bluebird bio position peaked at $74K in Q1 2019.
  • 158 funds tracked by Wall St. Rank held bluebird bio as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.